(Q43929321)

28 November 2017

Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis (English)

1 reference

28 November 2017

Kurt G Naber

1

1 reference

PubMed ID

12127707

28 November 2017

European Lomefloxacin Prostatitis Study Group

series ordinal

2

1 reference

PubMed ID

12127707

28 November 2017

language of work or name

1 reference

1 July 2002

1 reference

International Journal of Antimicrobial Agents

28 November 2017

1 reference

28 November 2017

20

1 reference

28 November 2017

1

1 reference

28 November 2017

18-27

1 reference

The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin.

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Pharmacokinetics of lomefloxacin in renally compromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Effect of food on absorption of lomefloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Penetration of lomefloxacin into human prostatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Proposed study design in prostatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900067-5

7 January 2021

10.1016/S0924-8579(02)00067-5

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

12127707